Sixty percent of colon cancer patients develop liver metastasis. Only 25% of those have potentially resectable hepatic metastases, and approximately 58% of those patients relapse.
Methods
We review the indications and the technical aspects of hepatic artery infusion (HAI) of chemotherapy, as well as the efficacy, morbidity, and outcomes.
Results
HAI of chemotherapy has been used following hepatic metastasectomy, in patients with unresectable metastases, or in combination with other agents. Floxuridine, the chemotherapeutic agent most studied, is administered through an implantable subcutaneous infusion pump connected to a surgically placed hepatic artery catheter, which delivers the chemotherapeutic agents at a slow fixed rate. Treatment-related toxicities include chemical hepatitis, biliary sclerosis, and peptic ulceration. Some trials report a survival benefit for HAI over systemic chemotherapy with acceptable toxicity.
Conclusions
Regional perfusion chemotherapy can be logistically and technically complicated to deliver. The development of newer systemic agents with superior efficacy in the treatment of metastatic colorectal cancer will likely diminish the role of regional perfusion therapy in the future.
References
1.
JemalA., MurrayT., WardE.Cancer statistics, 2005. CA Cancer J Clin.2005; 55: 10–30.
2.
CohenA.D., KemenyN.E.An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist.2003; 6: 553–566.
3.
FongY., FortnerJ., SunR.L.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg.1999; 230: 309–321.
4.
ScheeleJ., StanglR., Altendorf-HofmannA.Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg.1990; 77: 1241–1246.
5.
SullivanR.D., NorcrossJ.W., WatkinsE.Jr. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med.1964; 270: 321–327.
6.
AckermanN.B.The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery.1974; 75: 589–96.
HeinrichS., PetrowskyH., SchwinnenI.Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery.2003; 133: 40–48.
9.
CurleyS.A., ChaseJ.L., RohM.S.Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery.1993; 114: 928–935.
10.
CampbellK.A., BurnsR.C., StizmannJV. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol.1993; 11: 822–826.
11.
SkitzkiJ.J., ChangA.E.Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol.2002; 11: 123–135.
12.
KemenyN., SeiterK., NiedzwieckiD.A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer.1992; 69: 327–334.
13.
KemenyN., ContiJ.A., CohenA.Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol.1994; 12: 2288–2295.
BalchC.M., UristM.M., SoongS.J.A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg.1983; 198: 567–573.
16.
KemenyN., DalyJ., ReichmanB.Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med.1987; 107: 459–465.
17.
ChangA.E., SchneiderP.D., SugarbakerP.H.A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg.1987; 206: 685–693.
18.
HohnD.C., StaggR.J., FriedmanM.A.A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol.1989; 7: 1646–1654.
19.
SafiF., BittnerR., RoscherR.Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer.1989; 64: 379–387.
20.
WagmanL.D., KemenyM.M., LeongL.A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol.1990; 8: 1885–1893.
21.
MartinJ.K.Jr, O'ConnellM.J., WieandH.S.Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg.1990; 125: 1022–1027.
22.
RougierP., LaplancheA., HuguierM.Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol.1992; 10: 1112–1118.
23.
Allen-MershT.G., EarlamS., FordyC.Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet.1994; 344: 1255–1260.
24.
LorenzM., and MullerH.H.Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol.2000; 18: 243–254.
25.
KerrD.J., McArdleC.S., LedermannJ.Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet.2003; 361: 368–373.
26.
KemenyN.E., NeidzwieckiD., HollisD.R.Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Fla. Abstract 183.
27.
Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst.1996; 88: 252–258.
28.
HarmantasA., RotsteinL.E., LangerB.Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer.1996; 78: 1639–1645.
29.
KemenyN., GonenM., SullivanD.Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol.2001; 19: 2687–2695.
30.
LitvakD.A., WoodT.F., TsiouliasGJ. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol.2002; 9: 148–155.
31.
KemenyN., JarnaginW., PatyP.Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol.2003; 23: 4888–4896. Epub 2005 Jul 11.
32.
AlekshunT., GarrettC.Targeted therapies in the treatment of colorectal cancers. Cancer Control.2005; 12: 105–110.
33.
CurleyS.A., RohM.S., ChaseJ.L.Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg.1993; 166: 743–748.
34.
LorenzM., MullerH.H., SchrammH.Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg.1998; 228: 756–762.
35.
KemenyM.M., AdakS., GrayB.Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy. An intergroup study. J Clin Oncol.2002; 20: 1499–1505.
36.
KemenyN., HuangY., CohenA.M.Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med.1999; 341: 2039–2048.
37.
KemenyN.E., NiedzwieckiD., HollisD.R.Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. Proceedings from the Gastrointestinal Cancer Symposium 2005. Abstract 183.
38.
KemenyN., JarnaginW., GonenM.Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol.2003; 21: 3303–3309.
39.
KemenyN., EidA., StockmanJ.Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol.2005; 91: 97–101.
40.
DucreuxM., YchouM., LaplancheA.Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol.2005; 23: 4881–4887. Epub 2005 Jul 11.
41.
ZelekL., BugatR., CherquiD.Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol.2003; 14: 1537–1542.
